BRIEF published on 11/22/2024 at 18:05, 1 year 7 months ago MedinCell : Mise à jour du capital social et des droits de vote Droits De Vote Euronext Capital Social Actions Medincell
BRIEF published on 11/22/2024 at 18:05, 1 year 7 months ago MedinCell: Update of share capital and voting rights Share Capital Voting Rights Euronext Actions Medincell
PRESS RELEASE published on 11/22/2024 at 18:00, 1 year 7 months ago Informations privilégiées / Autres communiqués Euronext informe sur les droits de vote et le capital social de MedinCell. MedinCell, biopharmaceutique en France, développe des médicaments injectables à action prolongée Droits De Vote Euronext Capital Social Biopharmaceutique Medincell
BRIEF published on 11/06/2024 at 13:47, 1 year 7 months ago Medincell : Revenus 2024 à la hausse et avancée clinique significative Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
BRIEF published on 11/06/2024 at 13:47, 1 year 7 months ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 1 year 7 months ago Informations privilégiées / Autres communiqués Medincell relève ses prévisions de revenus UZEDY® de 25% et franchit une étape majeure dans l'essai clinique de l'Olanzapine LAI. Tous les détails dans le communiqué de presse de Teva pour le troisième trimestre 2024 Revenus Essai Clinique Medincell Teva UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 1 year 7 months ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
BRIEF published on 10/01/2024 at 15:47, 1 year 8 months ago Franchissement de seuil par Mirova dans MEDINCELL Capital Franchissement De Seuil Actions Medincell Mirova
BRIEF published on 10/01/2024 at 15:47, 1 year 8 months ago Threshold crossing by Mirova in MEDINCELL Capital Actions Threshold Crossing Medincell Mirova
PRESS RELEASE published on 10/01/2024 at 15:42, 1 year 8 months ago Franchissement de seuil Déclaration de franchissement de seuil par Mirova pour le compte de fonds gérés, détenant 7,07% du capital et 5,01% des droits de vote de MEDINCELL Acquisition Franchissement De Seuil AMF Medincell Mirova
Published on 06/27/2026 at 16:50, 1 day 2 hours ago Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 17 hours ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 18 hours ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 19 hours ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 20 hours ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/28/2026 at 17:26, 1 hour 33 minutes ago EQS-Adhoc: Correction of a release from 24/06/2026, 20:54 CET/CEST - Branicks Group AG sets out timetable for the publication of its 2025 annual and consolidated financial statements
Published on 06/27/2026 at 00:05, 1 day 18 hours ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 18 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 19 hours ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 19 hours ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
